Ignite Creation Date:
2025-12-26 @ 2:43 PM
Ignite Modification Date:
2026-01-26 @ 11:15 AM
Study NCT ID:
NCT02555306
Status:
COMPLETED
Last Update Posted:
2020-01-14
First Post:
2015-09-13
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration
Sponsor:
Santen Inc.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
36-001
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None